2020
Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and may Elicit NS1-Specific Antibody Responses in Vaccinated Individuals
SALÁT, Jiří, Kamil MIKULÁŠEK, Osmany LARRALDE, Petra POKORNÁ FORMANOVÁ, Aleš CHRDLE et. al.Základní údaje
Originální název
Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and may Elicit NS1-Specific Antibody Responses in Vaccinated Individuals
Autoři
SALÁT, Jiří (203 Česká republika), Kamil MIKULÁŠEK (203 Česká republika, domácí), Osmany LARRALDE, Petra POKORNÁ FORMANOVÁ, Aleš CHRDLE, Jan HAVIERNIK (203 Česká republika, domácí), Jana ELSTEROVÁ, Dana TEISLEROVÁ, Martin PALUS, Luděk EYER (203 Česká republika), Zbyněk ZDRÁHAL (203 Česká republika, domácí), Juraj PETRIK a Daniel RŮŽEK (203 Česká republika)
Vydání
Vaccines, Basel, MDPI, 2020, 2076-393X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10607 Virology
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.422
Kód RIV
RIV/00216224:14740/20:00115337
Organizační jednotka
Středoevropský technologický institut
UT WoS
000529439800080
Klíčová slova anglicky
NS1; flavivirus; tick-borne encephalitis; vaccination; vaccine
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 2. 11. 2024 20:35, Ing. Martina Blahová
Anotace
V originále
Vaccination against tick-borne encephalitis (TBE) is based on the use of formalin-inactivated, culture-derived whole-virus vaccines. Immune response following vaccination is primarily directed to the viral envelope (E) protein, the major viral surface antigen. In Europe, two TBE vaccines are available in adult and pediatric formulations, namely FSME-IMMUN (R) (Pfizer) and Encepur((R)) (GlaxoSmithKline). Herein, we analyzed the content of these vaccines using mass spectrometry (MS). The MS analysis revealed that the Encepur vaccine contains not only proteins of the whole virus particle, but also viral non-structural protein 1 (NS1). MS analysis of the FSME-IMMUN vaccine failed due to the high content of human serum albumin used as a stabilizer in the vaccine. However, the presence of NS1 in FSME-IMMUN was confirmed by immunization of mice with six doses of this vaccine, which led to a robust anti-NS1 antibody response. NS1-specific Western blot analysis also detected anti-NS1 antibodies in sera of humans who received multiple doses of either of these two vaccines; however, most vaccinees who received <= 3 doses were negative for NS1-specific antibodies. The contribution of NS1-specific antibodies to protection against TBE was demonstrated by immunization of mice with purified NS1 antigen, which led to a significant (p < 0.01) prolongation of the mean survival time after lethal virus challenge. This indicates that stimulation of anti-NS1 immunity by the TBE vaccines may increase their protective effect.
Návaznosti
90127, velká výzkumná infrastruktura |
|